Skip to main navigation
Skip to search
Skip to main content
Manipal Academy of Higher Education, Manipal, India Home
Help & FAQ
Link opens in a new tab
Search content at Manipal Academy of Higher Education, Manipal, India
Home
Profiles
Research units
Research output
Equipment
Newer drugs and targets in tuberculosis
Harish Thanu Subramanian
,
K. Meena Kumari
, V. Amberkar Mohan Babu
*
*
Corresponding author for this work
Department of Pharmacology, Kasturba Medical College, Manipal
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Newer drugs and targets in tuberculosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
INIS
drugs
100%
tuberculosis
100%
people
23%
inhibition
15%
synthesis
15%
children
7%
energy
7%
women
7%
patients
7%
doses
7%
rna polymerases
7%
antibodies
7%
antibiotics
7%
metabolism
7%
lead compounds
7%
rna
7%
hiv
7%
men
7%
atp
7%
ruthenium complexes
7%
Pharmacology, Toxicology and Pharmaceutical Science
Tuberculosis
100%
Extensively Drug-Resistant Tuberculosis
18%
Drug Development
9%
HIV
9%
Drug Discovery
9%
Multi-Drug-Resistant Tuberculosis
9%
Bedaquiline
9%
Clofazimine
9%
Malic Acid
9%
Cyclopeptide
9%
Delamanid
9%
N (2 Adamantyl) N' Geranylethylenediamine
9%
Nitazoxanide
9%
Ruthenium Complex
9%
Sutezolid
9%
Leucine Transfer RNA
9%
Pretomanid
9%
Lead Compound
9%
Rifampicin
9%
Biological Product
9%
Interleukin 4
9%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
9%
Adenosine Triphosphate
9%
Clavulanic Acid
9%
Meropenem
9%
Menaquinone
9%
RNA Polymerase
9%
Antimicrobial Agent
9%